Supernus Pharmaceuticals, Inc. (SUPN): R&D Expense
$106.23M
Year ended 2025-12-31
$126.09M
Trailing 12 months to 2026-06-30
+12.5%
3-year compound annual growth
+6.9%
5-year compound annual growth
+13.8%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $106.23M | -2.4% | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | $108.80M | +18.8% | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | $91.59M | +22.9% | 2026-03-02, From 2023-01-01 |
| 2022-12-31 | $74.55M | -17.6% | 2025-02-25, From 2022-01-01 |
| 2021-12-31 | $90.47M | +19.1% | 2023-03-09, From 2021-01-01 |
| 2020-12-31 | $75.96M | +9.9% | 2023-03-09, From 2020-01-01 |
| 2019-12-31 | $69.10M | -22.5% | 2022-04-13, From 2019-01-01 |
| 2018-12-31 | $89.21M | +79.9% | 2021-03-08, From 2018-01-01 |
| 2017-12-31 | $49.58M | +15.9% | 2020-02-28, From 2017-01-01 |
| 2016-12-31 | $42.79M | +46.9% | 2019-03-01, From 2016-01-01 |
| 2015-12-31 | $29.14M | +48.8% | 2018-03-01, From 2015-01-01 |
| 2014-12-31 | $19.59M | +13.6% | 2017-03-16, From 2014-01-01 |
| 2013-12-31 | $17.25M | -26.7% | 2017-01-20, From 2013-01-01 |
| 2012-12-31 | $23.52M | -23.2% | 2015-03-12, From 2012-01-01 |
| 2011-12-31 | $30.63M | -12.9% | 2014-03-21, From 2011-01-01 |
| 2010-12-31 | $35.15M | n/a | 2013-03-15, From 2010-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $106.23M | -2.4% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $85.84M | +16.1% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $117.31M | +43.8% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $53.20M | -24.8% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $254.91M | +3.2% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $96.85M | -13.2% |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | $750.00M | +7.4% |
| Collegium Pharmaceutical, Inc (COLL) | 2024-12-31 | $0 | n/a |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | $183.28M | -2.0% |
Compare SUPN, AMPH, PCRX, EBS side by side · Screen every company in Pharmaceutical Preparations ↗